Omega Advisors’s Array Biopharma Inc ARRY Stock Holding History

Omega Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-200,000	Closed	-$3.26M	–	110
2018 Q1	$3.26M	Buy	+200,000	New	+$3.2M	0.12%	67

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Omega Advisors's ARRY Position: Q2 2018 in Review

Omega Advisors sold out of Array Biopharma Inc (ARRY) in Q2 2018, closing a stake of 200,000 shares — an estimated $3.26M sold.

Omega Advisors first reported a position in ARRY in Q1 2018 and held it in 1 quarter. The position peaked at $3.26M in Q1 2018. 223 funds tracked by Wall St. Rank hold ARRY as of Q2 2018.

Omega Advisors reported no remaining Array Biopharma Inc position as of Q2 2018 after selling out during the quarter.
Omega Advisors sold 200,000 Array Biopharma Inc shares in Q2 2018, an estimated $3.26M.
Omega Advisors first reported a position in Array Biopharma Inc in Q1 2018 and held it in 1 quarter.
Omega Advisors's Array Biopharma Inc position peaked at $3.26M in Q1 2018.
223 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2018.

Based on Omega Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.